|Articles|February 19, 2016

What Lies Ahead 2016

Author(s)DIA

What Lies Ahead 2016

DIA’s exclusive annual survey catalogs, ranks, and describes trends to watch in biopharmaceutical, device, and related research, development, and regulation, from expert global and regional perspectives, in the year ahead.

Read the article here.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

What Lies Ahead 2016

Related Content

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading

Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb

The Shift Towards Globally Sourced Innovation

Why Dealmaking Is Now a Survival Skill: Q&A with Dan Chancellor

Trending on PharmExec

M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

When Drug Pricing Becomes Trade Policy

Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb

FDA Approves Pasatru For Adults With Fibrodysplasia Ossificans Progressiva